written on 27.03.2014

New NICE evals could green-light more drugs, but only at 'the very best price'


The U.K.'s cost watchdog is changing up the way it evaluates drugs. The National Institute for Health and Care Excellence (NICE) will be zooming out to look at the bigger picture when assessing therapies, which could result in more positive recommendations–something drugmakers have been dreaming of for years.